0,1,2,3,4,5,6
Table 7.1:  Overview phase III trials of PD-1 immune checkpoint inhibitors in adjuvant RCC,,,,,,
Phase III trial of PD-1 immune checkpoint inhibitors in adjuvant RCC,,,,,,
Study,N,Experimental   arm,Primary   endpoint,Risk groups,DFS (mo)  Median (95% CI)   HR,OS (mo.)  Median (95% CI)   HR
Keynote-564  NCT03142334  Median follow-up    of 30.1 mo. [440],994,PEMBRO  200 mg IV   Q3W    (17 cycles)    vs. placebo,DFS in   the ITT   by IR,"Intermediate-  high: pT2 grade   4 or sarcomatoid;   pT3 any grade  High: pT4 any   grade, pN1  M1 NED: cM0   after resection of   oligometastatic   disease < 12 mo.",(ITT)  PEMBRO: NR (NE)  PLACEBO: NR (NE)  HR: 0.63 (95% CI:   0.50–0.80)  p < 0.002  DFS at 24 mo.:  PEMBRO: 78.3%  PLACEBO: 67.3%,(ITT)  PEMBRO: NR (NE)  PLACEBO: NR (NE)  HR: 0.52 (95%    CI: 0.31–0.86)  not significant  alive at 30 mo.:  PEMBRO: 95.7%  PLACEBO: 91.4%
IMmotion010  NCT03024996  Median follow-up    of 44.7 mo. [442],778,ATEZO    1200 mg   IV Q3W (16   cycles or 1 yr.)   vs. placebo,DFS in   the ITT   by IR,"By TNM:    pT2 grade 4 or   sarcomatoid;   pT3 a grade 3–4;   pT3b/c/T4 any   grade, pN1  M1 NED: cM0   after resection of   oligometastatic   disease   (synchronous or    > 12 mo.)",(ITT)  ATEZO: 57.2    (44.6–NE)  PLACEBO: 49.5   (47.4–NE)  HR: 0.93 (95%    CI: 0.75–1.15)   p = 0.4950  DFS at 24 mo.: NR,(ITT)  ATEZO:    NE (59.8–NE)  PLACEBO:    NE (NE–NE)  HR : 0.97 (95%    CI: 0.67–1.42)  alive at 24 mo.: NR
CheckMate 914  NCT03138512  Median follow-up   of 37.0 mo. [443],,816 NIVO 240 mg    IV Q2W    (× 12 cycles) +   IPI 1 mg/kg    IV Q6W    (× 4 cycles vs.   placebo),DFS in   the ITT    by BICR,"By TNM:    pT2a grade 3–4;  pT2b/T3/T4 any   grade, pN1",(ITT)  NIVO + IPI: NR (NE)  PLACEBO: 50.7   (48.1–NE)  HR: 0.92 (95%    CI: 0.71–1.19)   p = 0.5347  DFS at 24 mo.:  NIVO + IPI: 76.4%  PLACEBO: 74.0%,NR
PROSPER  NCT03055013  Median follow-up:   NR [444],,779 Neoadjuvant   NIVO 240 mg    IV Q2W    (x 2 cycles)   followed by   adjuvant    NIVO 240 mg   Q2W for    3 mo. and   Q4W for   6 mo. vs.   observation,RFS in   the ITT   by IR,By TNM:    >/= cT2 (7 cm)    or cT any cN1,"(ITT), RFS:  NIVO: NR (NE)  Observation: NR   (NE)  HR: 0.97 (95%    CI: 0.74–1.28)   p = 0.43",(ITT)  NIVO: NR (NE)  Observation: NR   (NE)  HR: 1.48 (95%    CI: 0.89–2.48)   p = 0.93
Summary of evidence,LE,,,,,
"Adjuvant sorafenib, pazopanib, everolimus, girentuximab, or axitinib does not improve DFS or OS after   nephrectomy.",1b,,,,,
"In one single RCT, in selected high-risk patients, adjuvant sunitinib improved DFS but not OS.",1b,,,,,
Adjuvant pembrolizumab defined by the inclusion criteria of the trial* after nephrectomy improves DFS.,1b,,,,,
Adjuvant PD-L1 inhibition with atezolizumab did not improve DFS or OS.,1b,,,,,
Adjuvant dual PD-1 and CTLA-4 inhibition with nivolumab and ipilimumab did not improve DFS.,1b,,,,,
Peri-operative treatment with nivolumab did not improve RFS.,1b,,,,,
The lack of biomarker data is hindering progress in this field. Adjuvant RCTs are ongoing to evaluate   the benefit of adjuvant immunotherapy after nephrectomy in high-risk patients.,4,,,,,
Recommendations,Strength rating,,,,,
Discuss the contradictory results of the available adjuvant ICI trials with patients to facilitate   shared decision making.,Strong,,,,,
Inform patients about the potential risk of overtreatment and immune-related side effects if   adjuvant therapy is considered.,Strong,,,,,
"Do not offer adjuvant therapy with sorafenib, pazopanib, everolimus, girentuximab, or   axitinib.",Strong,,,,,
Do not offer adjuvant sunitinib following surgically resected high-risk clear-cell renal cell   carcinoma (ccRCC).,Weak,,,,,
"Offer adjuvant pembrolizumab to ccRCC patients, preferably within 12–16 weeks post-  nephrectomy, with a recurrence risk as defined in the Keynote-564 trial:  •   Intermediate-high risk:   •   pT2, grade 4 or sarcomatoid, N0, M0  •   pT3, any grade, N0, M0  •   High risk:  •   pT4, any grade, N0, M0  •   any pT, any grade, N+, M0  •   M1 no evidence of disease (NED):  •   NED after resection of oligometastatic sites < 1 year from nephrectomy",Weak,,,,,
